Ovidrel®/Ovitrelle® (choriogonadotropin alfa) is the world's first recombinant liquid prefilled chorionic gonadotropin (r-hCG) for the treatment of anovulation, or absence of ovulation, the most common cause of infertility in women. Anovulation is brought about by irregularities in the hormones needed to produce and release healthy eggs.

Ovidrel®/Ovitrelle® is administered after the stimulation of the growth of follicles (or eggs) by follicle stimulating hormone (FSH). It is used to trigger ovulation in women with anovulation and to promote final maturation of eggs in the ovaries of women undergoing assisted reproductive technologies (ART) such as in-vitro fertilization.

Ovidrel®/Ovitrelle® is produced by recombinant DNA technology and delivered in a liquid, prefilled syringe.